In the MEASURE 2 trial, the primary end point of MEASURE 2 (ASAS20 at Week 16) was achieved by 61% of patients vs 28% for placebo in a mixed population (2/3 biologic-naive, 1/3 anti–TNF-α inadequate responder)1
AS safety profile through Week 16 and Year 1: MEASURE 1 and 2 (pooled data, any dose)1,8*
- If a serious infection develops, discontinue COSENTYX until the infection resolves1
- If an anaphylactic reaction or other serious allergic reaction occurs, discontinue COSENTYX immediately and initiate appropriate therapy1
EAIR=exposure-adjusted incidence rate; IV=intravenous.
AS safety profile through Year 510-13
- Adverse reactions reported by >1% of patients in clinical trials for moderate to severe PsO were nasopharyngitis, diarrhea, upper respiratory tract infection, rhinitis, oral herpes, pharyngitis, urticaria, and rhinorrhea1
- The safety profile observed in patients with AS is consistent with PsO1
- Neutralizing antibodies developed in 0.6% of patients with PsO and were not associated with loss of efficacy14*
- Evaluate patients for TB infection prior to initiating treatment
Please see Important Safety Information, including CONTRAINDICATIONS.
IBD=inflammatory bowel disease; IL=interleukin; MACE=major adverse cardiovascular event; PsO=plaque psoriasis; PY=patient-years; TB=tuberculosis.
Positive injection experience with easy-to-use Sensoready® pen16*†‡
- The only IL-17A inhibitor demonstrated to have ≤1.6% low rate of injection site reactions in patients with AS and PsA at Week 1615
- >90% of patients reported no pain during or after the injection16
- Nearly 9 out of 10 patients reported being satisfied or very satisfied with self-injection using the Sensoready pen16
COSENTYX is the first and only fully human monoclonal antibody to selectively target IL-17A1
- IL-17A is a naturally occurring cytokine and an important mediator in the inflammatory process, which can cause joint damage in PsA and inflammation in AS, nr-axSpA, and PsA1,18
- Elevated levels of IL-17A are found in psoriatic plaques1
- Increased numbers of IL-17A–producing lymphocytes and innate immune cells and increased levels of IL-17A have been found in the blood of patients with AS and PsA. Increased numbers of IL-17A–producing lymphocytes have also been found in patients with nr-axSpA1
- Selectively binds to IL-17A, and inhibits its interaction with the IL-17 receptor1
- Inhibits the subsequent release of proinflammatory cytokines and chemokines1
- Selectively binds to IL-17A, and inhibits its interaction with the IL-17 receptor2
- Inhibits the subsequent release of proinflammatory cytokines and chemokines2
Clinical significance of the COSENTYX mechanism of action is unknown.
Images not drawn to scale.
The immune pathophysiology of PsO, PsA, AS, and nr-axSpA involves complex molecular mechanisms of action not shown in this graphic.
Th17=T helper 17.
Guaranteed access for eligible commercially insured patients
- In rheumatology, COSENTYX is included on 72% of formularies* for commercially insured patients27
- If coverage is denied, free COSENTYX for up to 2 years with the Covered Until You're Covered Program for your eligible† commercially insured patients while coverage is pursued‡
- $0 co-pay for 100% of your eligible† commercial patients§
is a free personal support program with a dedicated team of support specialists to provide your patients with financial support and adherence tools
- The Medisafe app|| can help your patients stay on track with COSENTYX
If your patients have any questions, feel free to direct them to visit www.cosentyx.com
or call 1-844-COSENTYX (1-844-267-3689)
Resources to get your patients started
MEASURE 2 (AS 1) Study Design1,3*†
MEASURE 2 was a multicenter, randomized, double-blind, placebo-controlled trial that evaluated 219 adult patients with active AS who received COSENTYX 75 mg, 150 mg, or placebo subcutaneous treatment at Weeks 0, 1, 2, 3, and 4, followed by the same dose every 4 weeks. At Week 16, patients who received placebo were rerandomized to either COSENTYX 75 mg or 150 mg every 4 weeks. The primary end point was the percentage of patients who achieved ASAS20 response at Week 16.1,3
References: 1. Cosentyx [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; May 2021. 2. Data on file. CAIN457F2310 Data Analysis Report. Novartis Pharmaceuticals Corp; May 2019. 3. Data on file. CAIN457F2310 Clinical Study Report. Novartis Pharmaceuticals Corp; November 2014. 4. Poddubnyy DA, Rudwaleit M, Listing J, Braun J, Sieper J. Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis. 2010;69(7):1338-1341. 5. Data on file. Conversion data tables for ankylosing spondylitis. Novartis Pharmaceuticals Corp; April 2019. 6. Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3-17. 7. Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res. 1999;12(4):247-255. 8. Data on file. AIN457H Summary of Clinical Safety in (Ankylosing Spondylitis). Novartis Pharmaceuticals Corp; February 2015. 9. Data on file. Data Analysis Report: Study AIN457/secukinumab. Novartis Pharmaceuticals Corp; May 2018. 10. Data on file. Selected EAIRs MEASURE 2 Year 5. Novartis Pharmaceuticals Corp; January 2020. 11. Data on file. Selected EAIRs MEASURE 2 Year 2. Novartis Pharmaceuticals Corp; January 2020. 12. Data on file. Selected EAIRs MEASURE 2 Year 3. Novartis Pharmaceuticals Corp; January 2020. 13. Data on file. Selected EAIRs MEASURE 2 Year 4. Novartis Pharmaceuticals Corp; January 2020. 14. Reich K, Blauvelt A, Armstrong A, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. J Eur Acad Dermatol Venereol. 2019;33(9):1733-1741. 15. Data on file. AIN457F Summary of Clinical Safety Appendix 1. Novartis Pharmaceuticals Corp; February 2015. 16. Nash P, Mease PJ, McInnes IB, et al; on behalf of the FUTURE 3 study group. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018;20(1):47. 17. Paul C, Lacour J-P, Tedremets L, et al; for the JUNCTURE Study Group. Efficacy, safety, and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082-1090. 18. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763-776. 19. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888-898. 20. Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167(4):717-724. 21. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010;10(7):479-490. 22. Kehl AS, Corr M, Weisman MH. Enthesitis: new insights into pathogenesis, diagnostic modalities, and treatment. Arthritis Rheumatol. 2016;68(2):312-322. 23. Smith JA, Colbert RA. Review: the interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol. 2014;66(2):231-241. 24. Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141-150. 25. Zeichner JA, Armstrong A. The role of IL-17 in the pathogenesis and treatment of psoriasis. J Clin Aesthet Dermatol. 2016;9(6)(suppl 1):S3-S6. 26. Keijsers RR, Joosten I, van Erp PE, Koenen HJ, van de Kerkhof PC. Cellular sources of IL-17 in psoriasis: a paradigm shift? Exp Dermatol. 2014;23(11):799-803. 27. Data on file. Cosentyx Access. Novartis Pharmaceuticals Corp; May 2021.